Brief: Oncosil Medical Posts FY26 Unit Sales Up 53%, Revenue Up 44% Versus FY25
30/07/2026 03:14
BRIEF-Oncosil Medical Posts FY26 Unit Sales Up 53%, Revenue Up 44% Versus FY25 July 30 (Reuters) - Oncosil Medical Ltd OSL.AX:
FY26 UNIT SALES UP 53%, REVENUE UP 44% VERSUS FY25
Further company coverage: OSL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncosil Medical
See all newsAustralia's OncoSil Medical gains most in over 2 months on reaching 100-th patient milestone
Brief: Oncosil Medical Says FDA Grants Hde Approval For Oncosil Device For Distal Cholangiocarcinoma
Brief: Oncosil Medical Posts FY26 Unit Sales Up 53%, Revenue Up 44% Versus FY25
Brief: Oncosil Medical Receives Saudi FDA Approval
Brief: Oncosil Medical Files For FDA Approval